De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Nuvation Bio Toekomstige groei
Future criteriumcontroles 2/6
Nuvation Bio is forecast to grow earnings and revenue by 41.2% and 58.4% per annum respectively while EPS is expected to grow by 50.5% per annum.
Belangrijke informatie
41.2%
Groei van de winst
50.5%
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 23.6% |
| Inkomstengroei | 58.4% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 16 Sep 2024 |
Recente toekomstige groei-updates
Recent updates
Nuvation Bio: Continuing To Justify A Buy Thesis With Catalysts In 2024
Aug 08Is Nuvation Bio (NYSE:NUVB) A Risky Investment?
Aug 07
Nuvation Bio: A Potentially Transformative Acquisition
Jun 20Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate
Mar 31Nuvation: Cash Is King, Science Is An Afterthought
Oct 03We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth
Sep 14Seth Klarman's Baupost adds Herbalife, Altice USA, exits Dropbox, Enhabit
Feb 14We're Hopeful That Nuvation Bio (NYSE:NUVB) Will Use Its Cash Wisely
Feb 10We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth
Nov 09Nuvation Bio GAAP EPS of -$0.12 beats by $0.02
Nov 03Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 29 | -197 | N/A | -152 | 2 |
| 12/31/2025 | 1 | -167 | N/A | -134 | 5 |
| 12/31/2024 | 1 | -547 | N/A | -86 | 5 |
| 6/30/2024 | 1 | -511 | -84 | -84 | N/A |
| 3/31/2024 | N/A | -69 | -64 | -64 | N/A |
| 12/31/2023 | N/A | -76 | -68 | -68 | N/A |
| 9/30/2023 | N/A | -83 | -69 | -69 | N/A |
| 6/30/2023 | N/A | -90 | -81 | -81 | N/A |
| 3/31/2023 | N/A | -105 | -91 | -91 | N/A |
| 12/31/2022 | N/A | -104 | -96 | -96 | N/A |
| 9/30/2022 | N/A | -108 | -104 | -103 | N/A |
| 6/30/2022 | N/A | -103 | -89 | -88 | N/A |
| 3/31/2022 | N/A | -88 | -79 | -78 | N/A |
| 12/31/2021 | N/A | -87 | -68 | -68 | N/A |
| 9/30/2021 | N/A | -75 | -58 | -58 | N/A |
| 6/30/2021 | N/A | -64 | -53 | -53 | N/A |
| 3/31/2021 | N/A | -53 | -43 | -43 | N/A |
| 12/31/2020 | N/A | -42 | -37 | -37 | N/A |
| 9/30/2020 | N/A | -38 | -33 | -33 | N/A |
| 6/30/2020 | N/A | -32 | -33 | -32 | N/A |
| 3/31/2020 | N/A | -33 | -30 | -29 | N/A |
| 12/31/2019 | N/A | -34 | -25 | -24 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: NUVB is forecast to remain unprofitable over the next 3 years.
Winst versus markt: NUVB is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: NUVB is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: NUVB's revenue (58.4% per year) is forecast to grow faster than the US market (8.7% per year).
Hoge groei-inkomsten: NUVB's revenue (58.4% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if NUVB's Return on Equity is forecast to be high in 3 years time